StockMacro
Menu

Revvity

$145.22 +50% in 6 monthsMarket cap $16.2B

RVTY on XNYS, Technology, Revvity, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 54% in a year, but a layoff notice covers 53 workers and quarterly revenue rose 4.3%.

  • BadShort interest at 5.8%, up 2.1% on the prior report
  • WatchPast layoff-notice companies beat sector by median 11.0 points over 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 4 Oct 2026

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Industry
Laboratory analytical instruments (Technology)
Employees
11,000
Website
revvity.com
Listed
NYSE, US
Last results
3 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 4 Oct 2026: revenue $728.9M, net income $62.3M.
Quarter to 2 Jan 2022: revenue $1.0B, net income $190.2MQuarter to 2 Jan 2022: revenue $1.0B, net income $190.2MQuarter to 3 Apr 2022: revenue $1.3B, net income $177.0MQuarter to 3 Apr 2022: revenue $1.3B, net income $177.0MQuarter to 3 Jul 2022: revenue $1.2B, net income $179.2MQuarter to 3 Jul 2022: revenue $1.2B, net income $179.2MQuarter to 2 Oct 2022: revenue $711.8M, net income $85.3MQuarter to 2 Oct 2022: revenue $711.8M, net income $85.3MQuarter to 1 Jan 2023: revenue $741.2M, net income $127.7MQuarter to 1 Jan 2023: revenue $741.2M, net income $127.7MQuarter to 2 Apr 2023: revenue $674.9M, net income $569.5MQuarter to 2 Apr 2023: revenue $674.9M, net income $569.5MQuarter to 2 Jul 2023: revenue $709.1M, net income $35.6MQuarter to 2 Jul 2023: revenue $709.1M, net income $35.6MQuarter to 1 Oct 2023: revenue $670.7M, net income $9.5MQuarter to 1 Oct 2023: revenue $670.7M, net income $9.5MQuarter to 31 Dec 2023: revenue –, net income $78.6MQuarter to 31 Mar 2024: revenue $649.9M, net income $26.0MQuarter to 31 Mar 2024: revenue $649.9M, net income $26.0MQuarter to 30 Jun 2024: revenue $691.7M, net income $55.4MQuarter to 30 Jun 2024: revenue $691.7M, net income $55.4MQuarter to 29 Sep 2024: revenue $684.0M, net income $94.4MQuarter to 29 Sep 2024: revenue $684.0M, net income $94.4MQuarter to 29 Dec 2024: revenue $729.4M, net income $94.6MQuarter to 29 Dec 2024: revenue $729.4M, net income $94.6MQuarter to 30 Mar 2025: revenue $664.8M, net income $42.2MQuarter to 30 Mar 2025: revenue $664.8M, net income $42.2MQuarter to 29 Jun 2025: revenue $720.3M, net income $53.9MQuarter to 29 Jun 2025: revenue $720.3M, net income $53.9MQuarter to 28 Sep 2025: revenue $698.9M, net income $46.7MQuarter to 28 Sep 2025: revenue $698.9M, net income $46.7MQuarter to 28 Dec 2025: revenue $772.1M, net income $98.4MQuarter to 28 Dec 2025: revenue $772.1M, net income $98.4MQuarter to 5 Apr 2026: revenue $711.1M, net income $40.7MQuarter to 5 Apr 2026: revenue $711.1M, net income $40.7MQuarter to 5 Jul 2026: revenue $729.7M, net income $51.8MQuarter to 5 Jul 2026: revenue $729.7M, net income $51.8MQuarter to 4 Oct 2026: revenue $728.9M, net income $62.3MQuarter to 4 Oct 2026: revenue $728.9M, net income $62.3M
2 Jan 2022RevenueNet incometallest bar $1.3B4 Oct 2026
See the numbers
Quarter toRevenueNet income
4 Oct 2026$728.9M$62.3M
5 Jul 2026$729.7M$51.8M
5 Apr 2026$711.1M$40.7M
28 Dec 2025$772.1M$98.4M
28 Sep 2025$698.9M$46.7M
29 Jun 2025$720.3M$53.9M
30 Mar 2025$664.8M$42.2M
29 Dec 2024$729.4M$94.6M
29 Sep 2024$684.0M$94.4M
30 Jun 2024$691.7M$55.4M
31 Mar 2024$649.9M$26.0M
31 Dec 2023–$78.6M
1 Oct 2023$670.7M$9.5M
2 Jul 2023$709.1M$35.6M
2 Apr 2023$674.9M$569.5M
1 Jan 2023$741.2M$127.7M
2 Oct 2022$711.8M$85.3M
3 Jul 2022$1.2B$179.2M
3 Apr 2022$1.3B$177.0M
2 Jan 2022$1.0B$190.2M
Fundamentals, 12 months to 4 Oct 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.9B $2.8B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +4.6% +5.0%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $253.2M $237.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.25 $1.99
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 49.6%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 12.6% 12.9% -7.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 8.6% 8.4% -10.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 3.5% -17.0%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $590.5M $497.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $592.8M $931.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $2.6B $3.2B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $2.0B $2.3B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.36 0.45
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $65.13
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 64.0 33.4
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.5 4.1
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 6.2 4.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.2 2.4
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 0.19% 0.82%

Latest = 12 months to 4 Oct 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
RevvityRVTY (this company) $16.2B64.05.5+4.6%8.6%
AvantorAVTR $10.1B29.81.5+0.9%5.1%
Bio-Rad Laboratories, Inc.Class ABIO $9.7B9.43.7+1.4%39.5%
IlluminaILMN $29.2B32.66.4+5.8%19.7%
BrukerBRKR $8.6Bloss2.5+2.2%-3.5%
Mettler-Toledo InternationalMTD $33.2B35.57.9+6.5%22.2%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$1.3M

bought $0, sold $1.3M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+14%

604 13F filers vs 532

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

112.1M shares held by 13F filers (30 Sep 2026) of 111.6M outstanding (6 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.8%

6.5M shares sold short (30 Oct 2026) of 111.6M outstanding (6 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.9

6.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.1%

6.4M shares sold short in the report before, 6.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

61%

61% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+4.3%

$728.9M vs $698.9M (quarter ended 4 Oct 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-22%

$14.3M vs $18.5M (quarter ended 4 Oct 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$578K

the 12 months before: $2.3M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$40K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

53

the 12 months before: 81

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

13

13 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

4.3×

13 articles in the last 7 days; its usual week has 3.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 113, 2.1× a year earlier
  • Layoff notice 53 workers

Price $145.22 on 20 Nov 2026, +54% over 12 months (12-month range $82.26 to $165.78)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $6.0M in the last 12 months (the 12 months before: -$5.0M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, -67% on the 12 months before.
Revenue per quarter. Revenue $728.9M in the latest quarter, +4.3% on a year earlier.
Capital spending per quarter. Capital spending $14.3M in the latest quarter, -22% on a year earlier.
Institutional holders (13F filers). 604 13F filers reported holding it in the latest 13F quarter, +23% on a year earlier.
Federal obligations. Federal obligations: $2.4M published in the last 12 months, +2.7% on the 12 months before.
Lobbying spend. Lobbying spend: $40K published in the last 12 months (none in the 12 months before).
Workers in WARN layoff notices. Workers in WARN layoff notices: 134 published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 113 vs usual 56.50 (2026-09-30); 2.1x the same period a year earlier
26 Sep 2026WARN layoff noticeRevvity, 53 workers, Lawrence, MA, MA
26 Sep 2026Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 53)
25 Mar 2026WARN layoff noticeRevvity, Inc., 29 workers, Boston, MA, MA
25 Mar 2026Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 29)
2 Dec 2025WARN layoff noticeRevvity, Inc., 52 workers, Lawrence, MA, MA
2 Dec 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 52)
24 Oct 20258-K and other filingsDirector or officer change
24 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Jan 20258-K and other filingsA major agreement ended
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 70 vs usual 39 (2024-09-30); 1.8x the same period a year earlier
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 68 vs usual 39 (2024-03-31); 1.9x the same period a year earlier
26 Jan 20248-K and other filingsDirector or officer change
26 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 May 2023Sharp changeQuarterly revenue change: quarterly revenue change, 674.9M vs usual 1.2B (2023-04-02); 0.5x the same period a year earlier
15 Mar 20238-K and other filingsCompleted an acquisition or asset sale
7 Mar 2023Sharp changeQuarterly revenue change: quarterly revenue change, 741.2M vs usual 1.2B (2023-01-01); 0.7x the same period a year earlier
15 Nov 2022Sharp changeQuarterly revenue change: quarterly revenue change, 711.8M vs usual 1.2B (2022-10-02); 0.6x the same period a year earlier
3 Oct 2022Lobbying filinglobbying engagement terminated (THE MAJORITY GROUP, LLC)
17 Aug 20228-K and other filingsDirector or officer change
22 Jul 20228-K and other filingsDirector or officer change
22 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 29.4M vs usual 20.3M (2022-04-03); 2.1x the same period a year earlier
8 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 32.4M vs usual 20.3M (2022-01-02); 1.6x the same period a year earlier
Insider net buying (open market)
Month from 1 Dec 2021: -$927K published
Month from 1 Mar 2022: -$1.1M published
Month from 1 Jun 2022: -$731K published
Month from 1 Jul 2022: -$827K published
Month from 1 Aug 2022: -$525K published
Month from 1 Dec 2022: -$9.1M published
Month from 1 Mar 2023: -$1.3M published
Month from 1 Apr 2023: -$1.0M published
Month from 1 Feb 2024: -$4.0M published
Month from 1 Mar 2024: -$1.4M published
Month from 1 Jun 2024: -$442K published
Month from 1 Aug 2024: -$513K published
Month from 1 Oct 2024: -$789K published
Month from 1 Dec 2024: -$2.1M published
Month from 1 Jan 2025: -$642K published
Month from 1 Feb 2025: -$2.2M published
Month from 1 May 2025: -$55K published
Month from 1 Aug 2025: -$45K published
Month from 1 Feb 2026: -$4.7M published
Month from 1 Apr 2026: -$7K published
Month from 1 Jul 2026: -$9K published
Month from 1 Sep 2026: -$1.3M published
Month from 1 Oct 2026: -$13K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2024: 4 published
Quarter from 1 Jul 2025: 3 published
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 2 Jan 2022: $1.0B, -24% on a year earlier; public on 2 Mar 2023
Quarter ended 3 Apr 2022: $1.3B, -3.7% on a year earlier; public on 11 May 2022
Quarter ended 3 Jul 2022: $1.2B, +0.1% on a year earlier; public on 10 Aug 2022
Quarter ended 2 Oct 2022: $711.8M, -39% on a year earlier; public on 15 Nov 2022
Quarter ended 1 Jan 2023: $741.2M, -28% on a year earlier; public on 2 Mar 2023
Quarter ended 2 Apr 2023: $674.9M, -46% on a year earlier; public on 13 May 2023
Quarter ended 2 Jul 2023: $709.1M, -42% on a year earlier; public on 10 Aug 2023
Quarter ended 1 Oct 2023: $670.7M, -5.8% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $649.9M, -3.7% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $691.7M, -2.5% on a year earlier; public on 7 Aug 2024
Quarter ended 29 Sep 2024: $684.0M, +2.0% on a year earlier; public on 7 Nov 2024
Quarter ended 29 Dec 2024: $729.4M; public on 26 Feb 2025
Quarter ended 30 Mar 2025: $664.8M, +2.3% on a year earlier; public on 7 May 2025
Quarter ended 29 Jun 2025: $720.3M, +4.1% on a year earlier; public on 6 Aug 2025
Quarter ended 28 Sep 2025: $698.9M, +2.2% on a year earlier; public on 5 Nov 2025
Quarter ended 28 Dec 2025: $772.1M, +5.9% on a year earlier; public on 25 Feb 2026
Quarter ended 5 Apr 2026: $711.1M, +7.0% on a year earlier; public on 13 May 2026
Quarter ended 5 Jul 2026: $729.7M, +1.3% on a year earlier; public on 12 Aug 2026
Quarter ended 4 Oct 2026: $728.9M, +4.3% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 2 Jan 2022: $32.4M, +61% on a year earlier; public on 4 Mar 2022
Quarter ended 3 Apr 2022: $29.4M, +106% on a year earlier; public on 11 May 2022
Quarter ended 3 Jul 2022: $23.2M, +14% on a year earlier; public on 10 Aug 2022
Quarter ended 2 Apr 2023: $20.9M, -29% on a year earlier; public on 13 May 2023
Quarter ended 1 Oct 2023: $22.4M; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $17.8M, -15% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $22.0M; public on 7 Aug 2024
Quarter ended 29 Sep 2024: $22.3M, -0.2% on a year earlier; public on 7 Nov 2024
Quarter ended 29 Dec 2024: $24.5M; public on 26 Feb 2025
Quarter ended 30 Mar 2025: $16.0M, -10% on a year earlier; public on 7 May 2025
Quarter ended 29 Jun 2025: $18.9M, -14% on a year earlier; public on 6 Aug 2025
Quarter ended 28 Sep 2025: $18.5M, -17% on a year earlier; public on 5 Nov 2025
Quarter ended 28 Dec 2025: $20.2M, -18% on a year earlier; public on 25 Feb 2026
Quarter ended 5 Apr 2026: $19.8M, +24% on a year earlier; public on 13 May 2026
Quarter ended 5 Jul 2026: $11.1M, -41% on a year earlier; public on 12 Aug 2026
Quarter ended 4 Oct 2026: $14.3M, -22% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 565; public on 14 Feb 2022
31 Mar 2022 report: 597; public on 16 May 2022
30 Jun 2022 report: 547; public on 15 Aug 2022
30 Sep 2022 report: 497; public on 14 Nov 2022
31 Dec 2022 report: 558; public on 14 Feb 2023
31 Mar 2023 report: 515; public on 15 May 2023
30 Jun 2023 report: 478; public on 14 Aug 2023
30 Sep 2023 report: 461; public on 14 Nov 2023
31 Dec 2023 report: 456; public on 14 Feb 2024
31 Mar 2024 report: 494; public on 15 May 2024
30 Jun 2024 report: 459; public on 14 Aug 2024
30 Sep 2024 report: 489; public on 14 Nov 2024
31 Dec 2024 report: 505; public on 14 Feb 2025
31 Mar 2025 report: 505; public on 15 May 2025
30 Jun 2025 report: 504; public on 14 Aug 2025
30 Sep 2025 report: 490; public on 14 Nov 2025
31 Dec 2025 report: 494; public on 17 Feb 2026
31 Mar 2026 report: 490; public on 15 May 2026
30 Jun 2026 report: 532; public on 14 Aug 2026
30 Sep 2026 report: 604; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $588K published
Month from 1 Dec 2021: $465K published
Month from 1 Jan 2022: $613K published
Month from 1 Feb 2022: $953K published
Month from 1 Mar 2022: $226K published
Month from 1 Apr 2022: $154K published
Month from 1 May 2022: $270K published
Month from 1 Jun 2022: $1.1M published
Month from 1 Jul 2022: $2.3M published
Month from 1 Aug 2022: $632K published
Month from 1 Sep 2022: $1.5M published
Month from 1 Oct 2022: $496K published
Month from 1 Nov 2022: $1.1M published
Month from 1 Dec 2022: $2.0M published
Month from 1 Jan 2023: $516K published
Month from 1 Feb 2023: $620K published
Month from 1 Mar 2023: $450K published
Month from 1 Apr 2023: $861K published
Month from 1 May 2023: $594K published
Month from 1 Jun 2023: $417K published
Month from 1 Jul 2023: $303K published
Month from 1 Aug 2023: $898K published
Month from 1 Sep 2023: $824K published
Month from 1 Oct 2023: $293K published
Month from 1 Nov 2023: $539K published
Month from 1 Dec 2023: $1.5M published
Month from 1 Jan 2024: $301K published
Month from 1 Feb 2024: $106K published
Month from 1 Mar 2024: $658K published
Month from 1 Apr 2024: $31K published
Month from 1 May 2024: -$4K published
Month from 1 Jun 2024: $40K published
Month from 1 Jul 2024: $227K published
Month from 1 Aug 2024: $141K published
Month from 1 Sep 2024: $737K published
Month from 1 Oct 2024: $150K published
Month from 1 Nov 2024: -$99K published
Month from 1 Dec 2024: $65K published
Month from 1 Jan 2025: $17K published
Month from 1 Feb 2025: -$8K published
Month from 1 Mar 2025: $2.0M published
Month from 1 May 2025: $12K published
Month from 1 Jun 2025: $27K published
Month from 1 Jul 2025: -$68K published
Month from 1 Aug 2025: $0 published
Month from 1 Sep 2025: $69K published
Month from 1 Oct 2025: $105K published
Month from 1 Nov 2025: $97K published
Month from 1 Dec 2025: -$41K published
Month from 1 Jan 2026: -$11K published
Month from 1 Feb 2026: $36K published
Month from 1 Mar 2026: $200K published
Month from 1 Apr 2026: $0 published
Month from 1 May 2026: $14K published
Month from 1 Jun 2026: $27K published
Month from 1 Jul 2026: $0 published
Month from 1 Aug 2026: $65K published
Month from 1 Sep 2026: -$13K published
Month from 1 Oct 2026: $2.1M published
Lobbying spend
Quarter from 1 Jan 2022: $70K published
Quarter from 1 Apr 2022: $70K published
Quarter from 1 Jul 2022: $70K published
Quarter from 1 Oct 2026: $40K published
Workers in WARN layoff notices
Month from 1 Dec 2025: 52 published
Month from 1 Mar 2026: 29 published
Month from 1 Sep 2026: 53 published

What is unusual now

  • Made public in the last 90 days: it saw 113 13F filers open a new position in the quarter ended 30 Sep 2026, 2.1× the same quarter last year; it also filed a WARN layoff notice covering 53 workers within 30 days (Lawrence, MA, MA).
  • Many funds opening a new position: saw 113 13F filers open a new position in the quarter ended 30 Sep 2026, 2.1× the same quarter last year Public on 16 Nov 2026.
  • WARN layoff notice: filed a WARN layoff notice covering 53 workers within 30 days (Lawrence, MA, MA) Public on 26 Sep 2026.
  • Insider net buying (open market): Insiders sold a net $6.0M in the last 12 months (the 12 months before: -$5.0M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 3 sales, $1.3M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
2 Oct 2026Anita GonzalesVP and CAOSellplanned in advance (10b5-1)84$155.48$13KForm 4
23 Sep 2026Maxwell KrakowiakPlease See RemarksSellplanned in advance (10b5-1)1,631$144.53$236KForm 4
18 Sep 2026Tajinder S VohraPlease See RemarksSellplanned in advance (10b5-1)7,330$140.88$1.0MForm 4
22 Jul 2026Anita GonzalesVice President and CAOSellplanned in advance (10b5-1)85$109.48$9KForm 4
22 Apr 2026Anita GonzalesVice President and CAOSellplanned in advance (10b5-1)80$92.80$7KForm 4
26 Feb 2026Miriame VictorPlease See RemarksSellplanned in advance (10b5-1); after exercising options1,862$97.13$181KForm 4
25 Feb 2026Michelle McMurry-HeathDirectorSell600$97.26$58KForm 4
6 Feb 2026Prahlad R. SinghPlease See RemarksSellplanned in advance (10b5-1); after exercising options25,525$100.21$2.6MForm 4

604 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 113 opened a position, 47 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
T. Rowe Price Associates Inc13.2M11.8%+7.7M+139%
T. Rowe Price Investment Management, Inc.8.6M7.73%-9.6M-53%
BlackRock, Inc.7.8M6.97%$1.2B+120K+1.6%
Janus Henderson Group Ltd.7.4M6.62%$1.1B
Vanguard Capital Management LLC7.3M6.56%$1.1B+19K+0.3%
EdgePoint Investment Group Inc.5.3M4.77%$814.5M-3.2M-38%
Vanguard Portfolio Management LLC4.7M4.25%$725.1M-28K-0.6%
State Street Corp4.4M3.92%$668.3M+28K+0.6%
Dimensional Fund Advisors LP3.4M3.06%$521.9M-15K-0.4%
FMR LLC (Fidelity)3.0M2.73%$466.1M+2.6M+555%

Federal contracts

All 10 federal contracts

1 new award in 12 months, $2.0M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
30 Sep 2026Department of Health and Human ServicesOffice of the Assistant Secretary for Financial Resources$2.0MNCATS REQUIRES ACCESS TO A FEDRAMP-AUTHORIZED ELECTRONIC LABORATORY NOTEBOOK (ELN) TO SUPPORT LABORATORY STUDIES WITH A CHEMISTRY FOCUS. THIS ACQUISITION WILL PROVIDE THE NECESSARY SERVICES TO OBTAIN FEDRAMP MODERATE AUTHORIZATION FOR THE REVVITY SIGUSAspending
5 Jul 2022Department of Health and Human ServicesCenters for Disease Control and Prevention$2.4MMAINTENANCE AND SERVICE AGREEMENT FOR PE EQUIPMENTUSAspending
15 Mar 2021Department of DefenseDepartment of the Army$1.2MOPERA PHENIX PLUS SYSTEMUSAspending
18 Dec 2020Department of Health and Human ServicesNational Institutes of Health$1.3MTHIS IS A COVID-19 RELATED CONTRACT ACTION FOR AN OPERA PHENIX HIGH CONTENT SCREENING IMAGER WITH THE FOLLOWING PART NUMBERS FROM MANUFACTURER PERKINELMER: HH14001000, HH14001001, HH14000122, HH14000303, HH14000344, HH18000001 HH14000502 HH18000002 HUSAspending
4 Jun 2018Department of Health and Human ServicesCenters for Disease Control and Prevention$4.5Mup to $4.6MIGF::OT::IGF MAINTENANCE AGREEMENTUSAspending
30 Sep 2013Department of LaborMine Safety and Health Administration$1.1MIGF::OT::IGF AWS UNITSUSAspending
5 Mar 2013Environmental Protection AgencyIGF::OT::IGF OTHER FUNCTIONS - BIOACTIVITY PROFILING OF THE TOXCAST LIBRARY TASK ORDER 1USAspending
21 Sep 2012Department of Health and Human ServicesCenters for Disease Control and PreventionSCICLONE SAMPLE PREPARATION SYSTEMS (SSPS)USAspending

Company events

All 41 company events

Nothing in 12 months; the latest was filed 24 Oct 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
24 Oct 2025Director or officer change8-K
7 Jan 2025Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
26 Jan 2024Director or officer change8-K
15 Mar 2023Signed a major agreement; Completed an acquisition or asset sale8-K
17 Aug 2022Director or officer change8-K
5 Aug 2022Signed a major agreement8-K
22 Jul 2022Director or officer change8-K
23 Sep 2021Private placement of securities (Form D)$2.2B sold of $2.2B offeredD

Reported lobbying spend: $40K in Q3 2026, $70K in Q2 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Sep 2022EndedThe Majority Group, LLCfor Perkinelmer (Fka Oxford Immuotech USA)Not statedFiling
17 Mar 2021NewRevvity, Inc.its own lobbyistsSARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies H.R. 1319, American Rescue Plan Act implementation, SARS-CoV-2 testing provisions; Newborn Screening Saves Lives Reauthorization Act; RDIS, Health issues, Budget, CAW, MED, Trade, Defense, Manufacturing, Agriculture, VET, Medicare/Medicaid, Pharmacy, Insurance, FOO, Homeland security, Science/technologyFiling
7 Dec 2020NewThe Majority Group, LLCfor Perkinelmer (Fka Oxford Immuotech USA)Covid-19 Test Kit identification, prevention, and production.MEDFiling

Layoff notices

All 3 layoff notices

1 notice in 12 months covering 53 workers. State WARN notices.

NoticeSiteWorkersJobs endSource
25 Sep 2026RevvityLawrence, MA, MA539 Dec 2025Notice
8 Oct 2025Revvity, Inc.Lawrence, MA, MA529 Dec 2025Notice
10 Sep 2025Revvity, Inc.Boston, MA, MA291 Jun 2026Notice
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

16 Dec 2020confirmed

Confirmed across sources Filings + Financials and Lobbying

Revvity (RVTY): reported revenue of $964.0M for the quarter ended 4 Oct 2020, 1.4× the same quarter last year, while it registered for federal lobbying for the first time in our data (The Majority Group, Llc). Two unrelated kinds of activity within 28 days.

  • Financials: Quarterly revenue change, became public on 17 Nov 2020
  • Lobbying: First lobbying registration, became public on 16 Dec 2020
2018-09-30: $674.3M2018-12-30: $756.3M2019-03-31: $648.7M2019-06-30: $722.5M2019-09-29: $706.9M2019-12-29: $805.5M2020-04-05: $652.4M2020-07-05: $811.7M2020-10-04: $964.0M
The quarter ended 4 Oct 2020 against the 8 quarters before it. this quarterearliernormal: $714.7M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 17 Nov 2020

Revvity reported revenue of $964.0M for the quarter ended 4 Oct 2020, 1.4× the same quarter last year.

This period
$964.0M (the quarter ended 4 Oct 2020)
Normal quarter (median of 8 earlier)
$714.7M
Typical spread (median absolute deviation)
$52.0M
How far from its usual level
+3.2
Same quarter last year
$706.9M
History used
4,109 days
2018-09-30: $674.3M2018-12-30: $756.3M2019-03-31: $648.7M2019-06-30: $722.5M2019-09-29: $706.9M2019-12-29: $805.5M2020-04-05: $652.4M2020-07-05: $811.7M2020-10-04: $964.0M
the quarter ended 4 Oct 20208 earlier quartersnormal: $714.7M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Lobbying: First lobbying registration became public on 16 Dec 2020

Revvity registered for federal lobbying for the first time in our data (The Majority Group, Llc).

Source coverage starts
13 Jul 2010
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 113 13F filers open a new position in the quarter ended 30 Sep 2026, 2.1× the same quarter last year.

    Same quarter last year: 55; its normal quarter is 56.5.

    See the evidence
    This period
    113 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    56.5
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +5.9
    Same quarter last year
    55
    History used
    4,748 days
    2024-09-30: 702024-12-31: 372025-03-31: 462025-06-30: 542025-09-30: 552025-12-31: 592026-03-31: 582026-06-30: 932026-09-30: 113
    the quarter ended 30 Sep 20268 earlier quartersnormal: 56.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 6 Oct 2026Government contracts record

    REVVITY SIGNALS SOFTWARE, INC.: new Department of Health and Human Services contract 7571TE26C00013 ($2.0M) (dated 30 Sep 2026)

  3. 26 Sep 2026Layoff notices change

    filed a WARN layoff notice covering 53 workers within 30 days (Lawrence, MA, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    53
    Window
    27 Aug 2026 to 26 Sep 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  4. 26 Sep 2026Layoff notices record

    WARN notice: Revvity, 53 workers, Lawrence, MA, MA (dated 25 Sep 2026)

  5. 25 Mar 2026Layoff notices change

    filed a WARN layoff notice covering 29 workers within 30 days (Boston, MA, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    29
    Window
    23 Feb 2026 to 25 Mar 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  6. 25 Mar 2026Layoff notices record

    WARN notice: Revvity, Inc., 29 workers, Boston, MA, MA (dated 10 Sep 2025)

  7. 2 Dec 2025Layoff notices change

    filed a WARN layoff notice covering 52 workers within 30 days (Lawrence, MA, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    52
    Window
    2 Nov 2025 to 2 Dec 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  8. 2 Dec 2025Layoff notices record

    WARN notice: Revvity, Inc., 52 workers, Lawrence, MA, MA (dated 8 Oct 2025)

  9. 24 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 24 Oct 2025Filings record

    Director or officer change

  11. 7 Jan 2025Filings record

    A major agreement ended

  12. 14 Nov 2024Institutional holdings change

    saw 70 13F filers open a new position in the quarter ended 30 Sep 2024, 1.8× the same quarter last year.

    Same quarter last year: 39; its normal quarter is 39.

    See the evidence
    This period
    70 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    39
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +5.2
    Same quarter last year
    39
    History used
    4,018 days
    2022-09-30: 392022-12-31: 772023-03-31: 352023-06-30: 332023-09-30: 392023-12-31: 392024-03-31: 682024-06-30: 352024-09-30: 70
    the quarter ended 30 Sep 20248 earlier quartersnormal: 39

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 15 May 2024Institutional holdings change

    saw 68 13F filers open a new position in the quarter ended 31 Mar 2024, 1.9× the same quarter last year.

    Same quarter last year: 35; its normal quarter is 39.

    See the evidence
    This period
    68 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    39
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +7.4
    Same quarter last year
    35
    History used
    3,835 days
    2022-03-31: 552022-06-30: 382022-09-30: 392022-12-31: 772023-03-31: 352023-06-30: 332023-09-30: 392023-12-31: 392024-03-31: 68
    the quarter ended 31 Mar 20248 earlier quartersnormal: 39

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  14. 26 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 26 Jan 2024Filings record

    Director or officer change

  16. 16 May 2023Financials change

    reported revenue of $674.9M for the quarter ended 2 Apr 2023, 46% below the same quarter last year.

    Same quarter last year: $1.3B; its normal quarter is $1.2B.

    See the evidence
    This period
    $674.9M (the quarter ended 2 Apr 2023)
    Normal quarter (median of 8 earlier)
    $1.2B
    Typical spread (median absolute deviation)
    $86.0M
    How far from its usual level
    -4.1
    Same quarter last year
    $1.3B
    History used
    5,019 days
    2021-04-04: $1.3B2021-07-04: $1.2B2021-10-03: $1.2B2022-01-02: $1.0B2022-04-03: $1.3B2022-07-03: $1.2B2022-10-02: $711.8M2023-01-01: $741.2M2023-04-02: $674.9M
    the quarter ended 2 Apr 20238 earlier quartersnormal: $1.2B

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 15 Mar 2023Filings record

    Completed an acquisition or asset sale

  18. 7 Mar 2023Financials change

    reported revenue of $741.2M for the quarter ended 1 Jan 2023, 28% below the same quarter last year.

    Same quarter last year: $1.0B; its normal quarter is $1.2B.

    See the evidence
    This period
    $741.2M (the quarter ended 1 Jan 2023)
    Normal quarter (median of 8 earlier)
    $1.2B
    Typical spread (median absolute deviation)
    $70.5M
    How far from its usual level
    -4.0
    Same quarter last year
    $1.0B
    History used
    4,928 days
    2021-01-03: $1.4B2021-04-04: $1.3B2021-07-04: $1.2B2021-10-03: $1.2B2022-01-02: $1.0B2022-04-03: $1.3B2022-07-03: $1.2B2022-10-02: $711.8M2023-01-01: $741.2M
    the quarter ended 1 Jan 20238 earlier quartersnormal: $1.2B

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  19. 15 Nov 2022Financials change

    reported revenue of $711.8M for the quarter ended 2 Oct 2022, 39% below the same quarter last year.

    Same quarter last year: $1.2B; its normal quarter is $1.2B.

    See the evidence
    This period
    $711.8M (the quarter ended 2 Oct 2022)
    Normal quarter (median of 8 earlier)
    $1.2B
    Typical spread (median absolute deviation)
    $70.5M
    How far from its usual level
    -4.2
    Same quarter last year
    $1.2B
    History used
    4,837 days
    2020-07-05: $811.7M2020-10-04: $964.0M2021-01-03: $1.4B2021-04-04: $1.3B2021-07-04: $1.2B2021-10-03: $1.2B2022-04-03: $1.3B2022-07-03: $1.2B2022-10-02: $711.8M
    the quarter ended 2 Oct 20228 earlier quartersnormal: $1.2B

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  20. 3 Oct 2022Lobbying record

    PERKINELMER (FKA OXFORD IMMUOTECH USA): lobbying engagement terminated (THE MAJORITY GROUP, LLC) (dated 1 Sep 2022)

  21. 17 Aug 2022Filings record

    Director or officer change

  22. 22 Jul 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 22 Jul 2022Filings record

    Director or officer change

  24. 11 Jul 2022Government contracts record

    REVVITY HEALTH SCIENCES, INC.: new Department of Health and Human Services contract 75D30122C14458 ($1.1M) (dated 5 Jul 2022)

  25. 17 May 2022Financials change

    spent $29.4M on capital projects in the quarter ended 3 Apr 2022, 2.1× the same quarter last year.

    Same quarter last year: $14.3M; its normal quarter is $20.3M.

    See the evidence
    This period
    $29.4M (the quarter ended 3 Apr 2022)
    Normal quarter (median of 8 earlier)
    $20.3M
    Typical spread (median absolute deviation)
    $1.9M
    How far from its usual level
    +3.2
    Same quarter last year
    $14.3M
    History used
    4,564 days
    2020-04-05: $20.5M2020-07-05: $16.6M2020-10-04: $20.3M2021-01-03: $20.1M2021-04-04: $14.3M2021-07-04: $20.4M2021-10-03: $32.8M2022-01-02: $32.4M2022-04-03: $29.4M
    the quarter ended 3 Apr 20228 earlier quartersnormal: $20.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  26. 8 Mar 2022Financials change

    spent $32.4M on capital projects in the quarter ended 2 Jan 2022, 1.6× the same quarter last year.

    Same quarter last year: $20.1M; its normal quarter is $20.3M.

    See the evidence
    This period
    $32.4M (the quarter ended 2 Jan 2022)
    Normal quarter (median of 8 earlier)
    $20.3M
    Typical spread (median absolute deviation)
    $1.6M
    How far from its usual level
    +5.2
    Same quarter last year
    $20.1M
    History used
    4,473 days
    2019-12-29: $23.2M2020-04-05: $20.5M2020-07-05: $16.6M2020-10-04: $20.3M2021-01-03: $20.1M2021-04-04: $14.3M2021-07-04: $20.4M2021-10-03: $32.8M2022-01-02: $32.4M
    the quarter ended 2 Jan 20228 earlier quartersnormal: $20.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  27. 16 Nov 2021Financials change

    spent $32.8M on capital projects in the quarter ended 3 Oct 2021, 1.6× the same quarter last year.

    Same quarter last year: $20.3M; its normal quarter is $20.2M.

    See the evidence
    This period
    $32.8M (the quarter ended 3 Oct 2021)
    Normal quarter (median of 8 earlier)
    $20.2M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +5.0
    Same quarter last year
    $20.3M
    History used
    4,382 days
    2019-09-29: $16.6M2019-12-29: $23.2M2020-04-05: $20.5M2020-07-05: $16.6M2020-10-04: $20.3M2021-01-03: $20.1M2021-04-04: $14.3M2021-07-04: $20.4M2021-10-03: $32.8M
    the quarter ended 3 Oct 20218 earlier quartersnormal: $20.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 23 Sep 2021Filings record

    Private placement of securities (Form D)

  29. 20 Sep 2021Filings record

    Completed an acquisition or asset sale

  30. 25 Aug 2021Filings record

    A major agreement ended

  31. 15 Jun 2021Government contracts record

    REVVITY HEALTH SCIENCES, INC.: new Department of Defense contract W81XWH21P0054 ($1.1M) (dated 15 Mar 2021)

  32. 18 May 2021Financials change

    reported revenue of $1.3B for the quarter ended 4 Apr 2021, 2.0× the same quarter last year.

    Same quarter last year: $652.4M; its normal quarter is $764.0M.

    See the evidence
    This period
    $1.3B (the quarter ended 4 Apr 2021)
    Normal quarter (median of 8 earlier)
    $764.0M
    Typical spread (median absolute deviation)
    $84.3M
    How far from its usual level
    +4.3
    Same quarter last year
    $652.4M
    History used
    4,291 days
    2019-03-31: $648.7M2019-06-30: $722.5M2019-09-29: $706.9M2019-12-29: $805.5M2020-04-05: $652.4M2020-07-05: $811.7M2020-10-04: $964.0M2021-01-03: $1.4B2021-04-04: $1.3B
    the quarter ended 4 Apr 20218 earlier quartersnormal: $764.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  33. 17 Mar 2021Lobbying record

    REVVITY, INC.: new lobbying registration (in-house)

  34. 9 Mar 2021Financials change

    reported revenue of $1.4B for the quarter ended 3 Jan 2021, 1.7× the same quarter last year.

    Same quarter last year: $805.5M; its normal quarter is $739.4M.

    See the evidence
    This period
    $1.4B (the quarter ended 3 Jan 2021)
    Normal quarter (median of 8 earlier)
    $739.4M
    Typical spread (median absolute deviation)
    $69.2M
    How far from its usual level
    +6.0
    Same quarter last year
    $805.5M
    History used
    4,200 days
    2018-12-30: $756.3M2019-03-31: $648.7M2019-06-30: $722.5M2019-09-29: $706.9M2019-12-29: $805.5M2020-04-05: $652.4M2020-07-05: $811.7M2020-10-04: $964.0M2021-01-03: $1.4B
    the quarter ended 3 Jan 20218 earlier quartersnormal: $739.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 24 Dec 2020Government contracts record

    REVVITY HEALTH SCIENCES, INC.: new Department of Health and Human Services contract 75N95021P00044 ($1.3M) (dated 18 Dec 2020)

  36. 16 Dec 2020several at once

    reported revenue of $964.0M for the quarter ended 4 Oct 2020, 1.4× the same quarter last year, while it registered for federal lobbying for the first time in our data (The Majority Group, Llc). Two unrelated kinds of activity within 28 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 17 Nov 2020

    Revvity reported revenue of $964.0M for the quarter ended 4 Oct 2020, 1.4× the same quarter last year.

    This period
    $964.0M (the quarter ended 4 Oct 2020)
    Normal quarter (median of 8 earlier)
    $714.7M
    Typical spread (median absolute deviation)
    $52.0M
    How far from its usual level
    +3.2
    Same quarter last year
    $706.9M
    History used
    4,109 days
    2018-09-30: $674.3M2018-12-30: $756.3M2019-03-31: $648.7M2019-06-30: $722.5M2019-09-29: $706.9M2019-12-29: $805.5M2020-04-05: $652.4M2020-07-05: $811.7M2020-10-04: $964.0M
    the quarter ended 4 Oct 20208 earlier quartersnormal: $714.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Lobbying: First lobbying registration became public on 16 Dec 2020

    Revvity registered for federal lobbying for the first time in our data (The Majority Group, Llc).

    Source coverage starts
    13 Jul 2010
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  37. 16 Dec 2020Lobbying change

    registered for federal lobbying for the first time in our data (The Majority Group, Llc).

    See the evidence (1 source record)
    Source coverage starts
    13 Jul 2010
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  38. 16 Dec 2020Lobbying record

    PERKINELMER (FKA OXFORD IMMUOTECH USA): new lobbying registration (THE MAJORITY GROUP, LLC) (dated 7 Dec 2020)

  39. 17 Nov 2020Financials change

    reported revenue of $964.0M for the quarter ended 4 Oct 2020, 1.4× the same quarter last year.

    Same quarter last year: $706.9M; its normal quarter is $714.7M.

    See the evidence
    This period
    $964.0M (the quarter ended 4 Oct 2020)
    Normal quarter (median of 8 earlier)
    $714.7M
    Typical spread (median absolute deviation)
    $52.0M
    How far from its usual level
    +3.2
    Same quarter last year
    $706.9M
    History used
    4,109 days
    2018-09-30: $674.3M2018-12-30: $756.3M2019-03-31: $648.7M2019-06-30: $722.5M2019-09-29: $706.9M2019-12-29: $805.5M2020-04-05: $652.4M2020-07-05: $811.7M2020-10-04: $964.0M
    the quarter ended 4 Oct 20208 earlier quartersnormal: $714.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  40. 1 Apr 2020Filings record

    Director or officer change

Showing the newest 40 of 67 entries; narrow the window or the kind of data to see older ones.

Not listed: 250 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000031791
Ticker
RVTY
Domain
revvity.com
Employer name
revity, REVVITY, INC. (1 unverified)
Fein
04-2052042 (1 unverified)
Hq location
MA|WALTHAM|02451 (1 unverified)
Lobbying client
perkinelmer fka oxford immuotech usa, revvity
Name
EG&G INC, PERKINELMER INC, Revvity, Inc.
Uei
XURJMC9NS4L3
Wikipedia
PerkinElmer, Revvity
  • DOL H-1B labor condition applications and PERM certifications37 data points29 Jul 2024 to 3 Aug 2026
  • Federal lobbying disclosures (LDA)3 records, 26 data points7 Dec 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)149 records4 Feb 2016 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1249 data points30 Dec 2007 to 6 Nov 2026
  • SEC Form 4 insider transactions126 records, 452 data points26 Feb 2016 to 2 Oct 2026
  • FINRA short interest (twice monthly)249 data points31 May 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1768 data points16 May 2023 to 20 Nov 2026
  • USASpending.gov federal awards10 records, 11335 data points1 Oct 2007 to 1 Oct 2026
  • WARN layoff notices (state labor agencies)3 records, 9 data points8 Sep 2025 to 25 Sep 2026
  • Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026